Development of the DexAide right ventricular assist device inflow cannula.

Cannula design and cannulation site can pose major limitations to chronic pump implantations in animal studies. The aim of this study was to evaluate the biocompatibility of various inflow cannula designs for the DexAide right ventricular assist device (RVAD). The DexAide RVAD was implanted for intended durations of 14, 30, or 90 days in 19 animals (mean 20 +/- 11 days). Seven inflow cannula designs were evaluated: angled titanium conduit with caged tip (two cases); flexible polyurethane coated polyvinyl chloride (PVC) tube (one case); open ended titanium (one case); a titanium cannula with a flange (six cases); a cannula with a gelatin coated flange (five cases); a cannula with an angled flange (one case); and open ended titanium with two side holes (three cases). The open ended titanium inflow cannula with two side holes positioned through the diaphragmatic surface of the right ventricle (RV) via a right thoracotomy showed good biocompatibility for the chronic animal study. Other cannulae inserted into the infundibular portion of the RV via a left thoracotomy showed significant depositions. Gelatin coated inflow cannula had the advantage to prevent tissue growth around the inflow cannula. The DexAide RVAD pump itself showed good biocompatibility, although nonadherent depositions originating from the inflow cannulae were captured onto the primary impeller blades.